The AHA/ACC started synthesizing evidence and publishing guidelines specifically for HTN in 2014. 1 This is a welcome addition to the guidelines as it fills an important gap in the most recent AHA/American College of Cardiology (ACC) recommendations. The American Heart Association (AHA) has recently released a new Scientific Statement regarding management of stage 1 HTN in adults with a low 10-year risk for CVD. In recent years, the incidence and prevalence of HTN have increased while rates of HTN control have declined. More cardiovascular disease (CVD) events are attributable to hypertension (HTN) than any other modifiable CVD risk factor. If blood pressure remains uncontrolled at 3-6 months, consider starting pharmacologic therapy.
The AHA/ACC has released a scientific statement in 2021 offering new guidance for management of stage 1 hypertension among patients with low ASCVD risk.
